London Stock Exchange welcomes AOTI, Inc. celebrating its successful listing on AIM

by Mike Hughes | Aug 19, 2024 | In The News

AOTI announces US FDA 510(k) Clearance of NEXA™ NPWT system for use in the home care setting

by Mike Hughes | Aug 19, 2024 | Press

AOTI, INC. (the “Company” or “Group” or “AOTI”) AOTI announces US FDA 510(k) Clearance of NEXA™ NPWT system for use in the home care setting Extension to Indications for Use follows submission of results from a human factors study evaluating the safe and effective use...

Treatment Recommendation for Diabetic Foot Ulcers (DFUs) by the Wound Healing Society

by Mike Hughes | Dec 4, 2023 | Press

AOTI’s at-home TWO2® therapy is able to deliver oxygen topically into chronic wounds, including Diabetic Foot Ulcers (DFUs), and to encourage high-quality, durable wound healing OCEANSIDE, Calif., Dec. 4, 2023 /PRNewswire/ — AOTI Inc., the global leader in...

AOTI to Present Keynote at Advanced Wound Care Summit Europe

by Mike Hughes | Nov 27, 2023 | Press

Dr. Mike Griffiths to lead discussions on durable wound healing at summit dedicated to advancing commercialization of cutting-edge wound care products OCEANSIDE, Calif., Nov. 27, 2023 /PRNewswire/ — AOTI Inc., the global leader in multimodality topical wound...

AOTI Participates in Panel Discussion at Preventing Diabetes-Related Amputations in America

by Mike Hughes | Jul 14, 2023 | Press

OCEANSIDE, Calif., July 14, 2023 /PRNewswire/ — AOTI Inc., the global leader in multimodality topical wound oxygen therapy, participated as a founding member of the Amputation Prevention Alliance (APA), in the “Preventing Diabetes-Related Amputations in...